Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy in Treating Patients With Stage II Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate within the past 6 months~  * Clinical stage T1-2c~* Combined Gleason score 2-6~* Prostate-specific antigen (PSA) \< 10 ng/mL within the past 6 months~  * PSA evaluated at least 10 days after prostate biopsy~ * For patients who received finasteride, PSA evaluated at least 30 after completion of finasteride~ * For patients who received dutasteride, PSA evaluated at least 90 after completion of dutasteride~* No regional lymph node involvement~* No distant metastases~PATIENT CHARACTERISTICS:~* Zubrod performance status 0-1~* No unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months~* No transmural myocardial infarction within the past 6 months~* No acute bacterial or fungal infection requiring IV antibiotics~* No chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study treatment~* No hepatic insufficiency resulting in clinical jaundice and/or coagulation defects~* No known AIDS~* No prior or concurrent lymphomatous/hematogenous malignancy or other invasive malignancy except nonmelanomatous skin cancer or any other cancer for which the patient has been continually disease-free for ≥ 5 years (e.g., carcinoma in situ of the bladder or oral cavity)~* No other severe, active comorbidity~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior radical prostatectomy or cryosurgery for prostate cancer~* No prior hormonal therapy, including any of the following:~  * Luteinizing hormone-releasing hormone agonists (e.g., goserelin or leuprolide)~ * Antiandrogens (e.g., flutamide or bicalutamide)~ * Estrogens \[e.g., diethylstilbestrol (DES)\]~ * Surgical castration (bilateral orchiectomy)~* No prior pelvic radiotherapy or prostate brachytherapy~* No prior or concurrent cytotoxic chemotherapy for prostate cancer~* At least 30 days since prior finasteride~* At least 90 days since prior dutasteride~* No concurrent neoadjuvant or adjuvant hormonal therapy~* Concurrent warfarin or other blood-thinning agents allowed

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Conventional 3D-CRT (Type: ACTIVE_COMPARATOR): Conventional 3D-CRT or IMRT to 73.8 Gy in 41 fractions
- Hypofractionated 3D-CRT (Type: EXPERIMENTAL): Hypofractionated 3D-CRT or IMRT to 70 Gy in 28 fractions

Based on this trial design, predict the completion outcome and termination type (if applicable).